"Quinoxalines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011810
|
| MeSH Number(s) |
D03.633.100.857
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinoxalines".
Below are MeSH descriptors whose meaning is more specific than "Quinoxalines".
This graph shows the total number of publications written about "Quinoxalines" by people in this website by year, and whether "Quinoxalines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2017 | 1 | 5 | 6 |
| 2018 | 10 | 6 | 16 |
| 2019 | 3 | 3 | 6 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Quinoxalines" by people in Profiles.
-
Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight. Biochem Biophys Res Commun. 2021 09 24; 571:26-31.
-
Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase. Sci Rep. 2021 05 13; 11(1):10290.
-
Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir. Sci Rep. 2021 03 31; 11(1):7307.
-
Novel Synthetic Routes to Prepare Biologically Active Quinoxalines and Their Derivatives: A Synthetic Review for the Last Two Decades. Molecules. 2021 Feb 18; 26(4).
-
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. Infect Genet Evol. 2020 10; 84:104451.
-
Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. Biosci Rep. 2020 06 26; 40(6).
-
Quinoxaline Derivatives as Antiviral Agents: A Systematic Review. Molecules. 2020 Jun 16; 25(12).
-
Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach. Comput Biol Med. 2020 07; 122:103848.
-
Smell and taste dysfunction in patients with SARS-CoV-2 infection: A review of epidemiology, pathogenesis, prognosis, and treatment options. Asian Pac J Allergy Immunol. 2020 Jun; 38(2):69-77.
-
Erdafitinib for advanced urothelial carcinoma. Lancet Oncol. 2019 09; 20(9):e469.